Rosuvastatin Enhances Angiogenesis via eNOS-Dependent Mobilization of Endothelial Progenitor Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zhou, Junlan ^a   Cheng, Min ^a   Liao, Yu Hua ^a   Hu, Yu ^b   Wu, Min ^b   Wang, Qing ^c   Qin, Bo ^d   Wang, Hong ^e   Zhu, Yan ^e   Gao, Xiu Mei ^e   Goukassian, David ^f   Zhao, Ting C ^g   Tang, Yao Liang ^h   Kishore, Raj ^a   Qin, Gangjian ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d NORTHWESTERN UNIVERSITY   (United States)

^e TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; ROSUVASTATIN; SIMVASTATIN; SODIUM CHLORIDE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BONE MARROW TRANSPLANTATION; CAPILLARY DENSITY; CELL DIFFERENTIATION; CELL MOBILIZATION; CELL MOTION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL PROGENITOR CELL; HINDLIMB ISCHEMIA; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE;

ANIMALS; BONE MARROW; CELL DIFFERENTIATION; CELL LINEAGE; CELL MOVEMENT; ENDOTHELIAL CELLS; FLUOROBENZENES; HINDLIMB; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PYRIMIDINES; REGIONAL BLOOD FLOW; STEM CELLS; SULFONAMIDES;

EID: 84877934261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063126     Document Type: Article

References (60)

1. Wollert KC, Drexler H, (2010) Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol 7: 204-215.
2. Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, et al. (2011) Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 109: 428-436.
3. Chavakis E, Koyanagi M, Dimmeler S, (2010) Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back. Circulation 121: 325-335.
4. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, et al. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221-228.
5. Qin G, Ii M, Silver M, Wecker A, Bord E, et al. (2006) Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med 203: 153-163.
6. Ziebart T, Yoon CH, Trepels T, Wietelmann A, Braun T, et al. (2008) Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res 103: 1327-1334.
7. Dimmeler S, Zeiher AM, Schneider MD, (2005) Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 115: 572-583.
8. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ, (2011) Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 50: 280-289.
9. Rehman J, Li J, Orschell CM, March KL, (2003) Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107: 1164-1169.
10. Sahoo S, Klychko E, Thorne T, Misener S, Schultz KM, et al. (2011) Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res 109: 724-728.
11. Xiong Q, Ye L, Zhang P, Lepley M, Swingen C, et al. (2012) Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells. Circ Res 111: 455-468.
12. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, et al. (2004) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 5: 81-87.
13. Levine GN, Keaney JF Jr, Vita JA, (1995) Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 332: 512-521.
14. Brautbar A, Ballantyne CM, (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol 8: 253-265.
15. Heart Protection Study Collaborative G (2007) Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45: 645-654; discussion 653-644.
16. Group TL-TIwPiIDLS (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357.
17. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
18. Koren MJ, Hunninghake DB, Investigators A, (2004) Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 44: 1772-1779.
19. Yemisci M, Ay H, Kocaefe C, Qui J, Topalkara K, et al. (2008) Statin potentiates human platelet eNOS activity without enhancing eNOS mRNA and protein levels. Cerebrovasc Dis 26: 190-198.
20. Merla R, Ye Y, Lin Y, Manickavasagam S, Huang MH, et al. (2007) The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol 293: H1918-1928.
21. Kosmidou I, Moore JP, Weber M, Searles CD, (2007) Statin treatment and 3' polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol 27: 2642-2649.
22. Wang CY, Liu PY, Liao JK, (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14: 37-44.
23. Bir SC, Xiong Y, Kevil CG, Luo J, (2012) Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases. Cardiovasc Res 95: 7-18.
24. Lemarie CA, Shbat L, Marchesi C, Angulo OJ, Deschenes ME, et al. (2011) Mthfr deficiency induces endothelial progenitor cell senescence via uncoupling of eNOS and downregulation of SIRT1. Am J Physiol Heart Circ Physiol 300: H745-753.
25. Qiu FY, Song XX, Zheng H, Zhao YB, Fu GS, (2009) Thymosin beta4 induces endothelial progenitor cell migration via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol 53: 209-214.
26. Duda DG, Fukumura D, Jain RK, (2004) Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 10: 143-145.
27. Suzuki G, Iyer V, Cimato T, Canty JM Jr (2009) Pravastatin improves function in hibernating myocardium by mobilizing CD133+ and cKit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle. Circ Res 104: 255-264, 210p following 264.
28. Walter DH, Dimmeler S, Zeiher AM, (2004) Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med 4: 385-393.
29. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, et al. (2001) Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103: 2885-2890.
30. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, et al. (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92: 152-160.
31. Clearfield MB, Amerena J, Bassand JP, Hernandez Garcia HR, Miller SS, et al. (2006) Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia-Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 7: 35.
32. Qin G, Kishore R, Dolan CM, Silver M, Wecker A, et al. (2006) Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A 103: 11015-11020.
33. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, et al. (2006) Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 113: 1605-1614.
34. Cheng M, Zhou J, Wu M, Boriboun C, Thorne T, et al. (2010) CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activity. Circ Res 107: 1083-1093.
35. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, et al. (2009) Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 104: 1209-1216.
36. Zhou J, Zhu Y, Cheng M, Dinesh D, Thorne T, et al. (2009) Regulation of vascular contractility and blood pressure by the E2F2 transcription factor. Circulation 120: 1213-1221.
37. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, et al. (2001) HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108: 399-405.
38. Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N, (2012) Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol 52: 83-92.
39. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, et al. (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370-1376.
40. Urbich C, Dernbach E, Zeiher AM, Dimmeler S, (2002) Double-edged role of statins in angiogenesis signaling. Circ Res 90: 737-744.
41. Weis M, Heeschen C, Glassford AJ, Cooke JP, (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739-745.
42. Katsumoto M, Shingu T, Kuwashima R, Nakata A, Nomura S, et al. (2005) Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 69: 1547-1555.
43. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, et al. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010.
44. Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui DS, et al. (2000) Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 106: 15-24.
45. Laufs U, Liao JK, (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271.
46. Skaletz-Rorowski A, Walsh K, (2003) Statin therapy and angiogenesis. Curr Opin Lipidol 14: 599-603.
47. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
48. Preiss D, Sattar N, (2012) Pharmacotherapy: Statins and new-onset diabetes-the important questions. Nat Rev Cardiol 9: 190-192.
49. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735-742.
50. Cheng M, Qin G, (2012) Progenitor cell mobilization and recruitment: SDF-1, CXCR4, alpha4-integrin, and c-kit. Prog Mol Biol Transl Sci 111: 243-264.
51. Papayannopoulou T, Scadden DT, (2008) Stem-cell ecology and stem cells in motion. Blood 111: 3923-3930.
52. Liu S, Rose DM, Han J, Ginsberg MH, (2000) Alpha4 integrins in cardiovascular development and diseases. Trends Cardiovasc Med 10: 253-257.
53. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ, (2001) Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 98: 1289-1297.
54. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, et al. (2001) Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 88: 167-174.
55. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, et al. (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434-438.
56. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, et al. (2001) Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97: 3354-3360.
57. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, et al. (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108: 391-397.
58. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
59. Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T, et al. (1999) The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol 9: 845-848.
60. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601.